Astellas Pharma’s Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment
Astellas Pharma (TYO: 4503) has announced that the U.S. Food and Drug Administration (FDA) has...
TYO: 4503
Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion
Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...
Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment
TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...
Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...
Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...
Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...
Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is...
Astellas Invests USD 90 Million in New US Facility to Boost Research and Commercialization
Japanese pharmaceutical company Astellas Pharma Inc. (TYO: 4503) has inaugurated a state-of-the-art laboratory and office...
Astellas Pharma Inc. Reports Revenue Growth in FY2023, Driven by Xtandi and Padcev Sales
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the year ended...
Astellas Pharma’s Padcev Combo Therapy Accepted for Review in China for Urothelial Carcinoma
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that China’s Center...
Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial
Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...
Astellas Launches Late-Stage Trial in Japan for Nonhormonal Menopause Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, last week initiated a late-stage...
Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies
Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first...
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the...
Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...
Astellas Pharma Appoints Zhao Ping as Chairman of China Operations
Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...
Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies
The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...